Rolipram
Description
Product Description
Rolipram
Application Notes
Rolipram compound has been shown to inhibit PDE4 activity in human cavernosal tissue, which interrupts the signal transduction pathway of erectile response. Rolipram promotes apoptosis in HL60 cells through a cAMP-independent mechanism and has been shown to enhance neuronal survival. It is a cAMP-specific phosphodiesterase inhibitor, selective for phosphodiesterase IV.
Usage Statement
Research Use Only (RUO). Ready for CE IVD labeling of clinical applications.
Key Applications
Enzyme||Inhibitors||Substrates
Specifications
| SKU | 0215981080 |
| Application Notes | Rolipram compound has been shown to inhibit PDE4 activity in human cavernosal tissue, which interrupts the signal transduction pathway of erectile response. Rolipram promotes apoptosis in HL60 cells through a cAMP-independent mechanism and has been shown to enhance neuronal survival. It is a cAMP-specific phosphodiesterase inhibitor, selective for phosphodiesterase IV. |
| Biochemical Physiological Actions | Selective cAMP-specific phosphodiesterase (PDE4) inhibitor. |
| EC Number | 262-771-1 |
| Format | powder |
| Hazard Statements | H315-H319-H335 |
| Applications | Enzyme||Inhibitors||Substrates |
| Molecular Formula | C16H21NO3 |
| Molecular Weight | 275.348 g/mol |
| Pack Size | 100 mg |
| Personal Protective Equipment | Dust mask, Eyeshields, Gloves |
| Physical Appearance | White Powder |
| Product Families Description | Rolipram |
| Product Overview | Rolipram |
| RTECS Number | UY5749237 |
| Safety Symbol | GHS07 |
| Storage and Handling | Store at +4 °C. |
| Usage Statement | Research Use Only (RUO). Ready for CE IVD labeling of clinical applications. |